Na manuia le Lymphoma Ausetalia i le mauaina o se fesoasoani mai le lalolagi atoa mai le AbbVie e faia ai faatalatalanoaga ma tagata tomai faapitoa mai Ausetalia ma faavaomalo i le lymphoma ma le gasegase lymphocytic leukemia (CLL). O fa'atalanoaga o le a lipotia ai fa'amatalaga lata mai e uiga i lymphoma/CLL fa'ata'ita'iga ma su'esu'ega mai le lalolagi atoa ma sa tu'uina atu i le taimi o le fonotaga a le ASH. O nei fa'atalanoaga o le a fa'asoa atu i le lalolagi atoa e ala i vaega fa'apitoa mo tagata ma'i.
O le Lymphoma Ausetalia na faia le toeitiiti atoa le 40 faatalanoaga i le 4 aso o le fonotaga ma matou te fia momoli atu le faafetai mai le taele o le lymphoma / CLL community ia i latou uma na faasoa mai o latou taimi, poto ma tomai ia i matou.
Lymphoma sela B
Dr Laurie Sehn - ASH Lymphoma Fa'afouga.
Dr Laurie Sehn mai le British Columbia Cancer Center mai Vancouver, Kanata o le Taitaifono o le komiti faufautua faafomai mo le International Lymphoma Coalition. Na talanoaina e Dr Sehn nisi o mea taua i togafitiga fou na tuuina atu i le taimi o le fonotaga a le ASH mo le lymphoma. E aofia ai le Polatuzumab (antibody drug conjugate) mo le diffuse large B-cell lymphoma (DLBCL) ma Mosunetuzumab - (bispecific antibody) fa'aoga mo lymphomas non-Hodgkin sela B.Dr Chan Cheah - Laasaga I Suesuega TG-1701 Relapsed po'o Refractory B-cell Lymphoma.
A/Prof Chan Cheah, Consultant Haematologist, Sir Charles Gairdner Hospital, Hollywood Private Hospital & Blood Cancer Research WA, i Perth, Western Australia, na talanoaina se faʻasalalauga faʻasalalau i le ASH o se faʻataʻitaʻiga na faia i Ausetalia e faʻaaoga ai se tupulaga fou Bruton's Tyrosine Kinase (BTK) inhibitor ua taʻua o le TG-1701 faʻaaogaina i tagata mamaʻi ua toe faʻafoʻi / refractor B-cell malignancies. O lenei vaila'au tu'u gutu e tu'uina atu e fai ma sui e tasi fa'atasi ma le umbralisib (PI3K inhibitor) ma le ubiltuximab (glycoengineered anti-CD20 monoclonal antibody).Ua Mulimuli Dr George – Lymphoma Updates.
Dr George Follows o le Lymphoma/CLL Clinical Lead mo Cambridge ma o lo'o ia umia foi le tele o tofiga e aofia ai le ta'ita'ifono o le UK CLL forum. Na fa'atalanoaina e Dr Follows fa'afouga mo le lymphoma na tu'uina atu i le taimi o le fonotaga a le ASH. O nei mea e aofia ai le vaega I faʻataʻitaʻiga e faʻaaoga ai se vailaʻau fou e taʻua o le Monunetuzumab o se faʻamaʻi monoclonal antibody e faʻatatau i le CD3 ma le CD20 ma ua taʻitaʻia ai tali tumau i tagata mamaʻi e maua i le lymphoma B-cell non-Hodgkin, e aofia ai maʻi na toe foʻi mai le CAR T. -togafitiga sela.
Dr Stephen Schuste - Mosunetuzumab faʻaosoina faʻamagalo atoatoa tumau i tagata mamaʻi ma le B-cell non-Hodgkin lymphoma.
O le monoclonal antibody Mosunetuzumab, lea e taulaʻi i le CD3 ma le CD20, na taʻitaʻia ai tali tumau i tagata mamaʻi ma le B-cell non-Hodgkin lymphoma (NHL), e oʻo lava ia i latou na maua i faʻamaʻi na toe faʻafoʻi pe faʻafefe i le chimeric antigen receptor (CAR) T- togafitiga sela. Na talanoaina e Dr Schuste le faʻaauauina o le I / Ib suʻesuʻega (GO29781; NCT02500407) o le mosunetuzumab i tagata gasegase e maua i le B-cell non-Hodgkin lymphoma (NHL), oe ua toe faʻafoʻi / refractory (R / R) i togafitiga CAR-T poʻo ai foi tuai i togafitiga aoga e le aofia ai lenei faiga. Fa'amatalaga muamua e lagolagoina e mosunetuzumab e lelei le fa'amalieina ma le aoga umi i le NHL R/R B-cell NHL na mua'i togafitia.
Dr John Leonard - fa'ailoga mai le fonotaga mo le lymphoma.
Na talanoaina e Dr Leonard ona manatu faʻapitoa mai faʻaaliga lymphoma i le taimi o le fonotaga. Na ia talanoaina le tele o mataupu e aofia ai: • Follicular lymphoma – chemo free regimens • Diffuse Large B-cell Lymphoma – soifua maloloina o ponaivi i gasegase pe a uma le R-CHOP ma le CAR T-cell therapy • Mantle Cell Lymphoma – vailaʻau fou faʻatasi ma le chemotherapy • Su'ega toto o le DNA • Vaccine Lymphoma
Lymphocytic Leukemia (CLL) & Small Lymphocytic Leukemia (SLL)
Dr Brian Koffman - CLL faʻafouga & faʻatonuga faʻamaʻi.
O Dr. Koffman, o se fomaʻi taʻutaʻua, faiaoga ma polofesa falemaʻi na liliu CLL maʻi, ua tuuto atu o ia lava e aʻoaʻo ma fesoasoani i le CLL community talu mai lona faʻamaʻi i le 2005. E talitonu Dr. Koffman o lona tulaga lua o se fomaʻi ma le maʻi e maua ai se tulaga tulaga ese. poto masani ma le malamalama e mafai ai e ia ona tuʻuina atu faʻamatalaga manino o mataupu lavelave ma fautua mo ona uso maʻi ma logoina ana uo tausi soifua maloloina. E taua tele lenei mea pe a va'ai i le suiga vave o le laufanua fa'afoma'i. O Dr Koffman o le tasi na faavaeina le CLL Society, ISA. Na talanoaina e Dr Koffman le CLL faʻafouga mai le konafesi e aofia ai faʻamatalaga e uiga i le CAR T-cell therapy, ibrutinib, acalabrutinib, faʻasologa o vailaʻau ma togafitiga tuʻufaʻatasiga eseese. Na ia talanoaina foʻi le pulega sili o le CLL, e aofia ai suʻesuʻega faʻapitoa aʻo leʻi faia togafitiga ma i latou e maua i faʻamaʻi e le suia, 17p del e le tatau ona faia le chemotherapy, ae faʻatatau i togafitiga.
Polofesa John Gribben ma Deborah Sims - Vaʻaiga lautele o togafitiga CLL.
Na talanoaina e Prof Gribben lona manatu i faʻamatalaga mai le fonotaga lea na faʻamalosia ai le tele o faʻamatalaga e faʻapea o togafitiga o loʻo faʻaaogaina e lelei ona ua umi le tulitatao. Faatasi ai ma se tulitatao umi e oʻo mai ai foi le malamalama o mea oona fou e ono aliali mai. Ona mafai lea ona tatou aʻoaʻoina lelei tagata mamaʻi i le mauaina o se manatu sili atu i mea e faʻamoemoeina. Na ia fa'atalanoaina fo'i fa'ata'ita'iga fou a le tupulaga ua fa'alauiloa mai, e le gata i le CLL, ae o isi fo'i lymphomas e pei ole Follicular lymphoma & Mantle cell lymphoma. E tele fo'i fa'ata'ita'iga fa'ata'ita'i fa'ata'ita'i fa'atasi ma vaila'au fou e fa'aalia ai le folafolaga. O le isi atugaluga o le fa'atasi ai ma nei fa'ata'ita'iga fa'afoma'i ma togafitiga tu'ufa'atasi, e sau ai se fa'aopoopoga o tupe fa'aalu mo le soifua maloloina.
Polofesa Stephan Stilgenbauer ma Deborah Sims - Faʻafouga ile pulega ole CLL/SLL.
Polofesa Stilgenbauer na tuʻuina atu se aotelega o faʻafouga togafitiga mo tagata mamaʻi ma CLL / SLL mai le fonotaga a le ASH. Na ia talanoaina le faʻaogaina o togafitiga faʻapitoa e avea ma sui nofofua ma faʻatasi o loʻo i ai ni taunuuga taua mo tagata mamaʻi, aemaise lava i latou o loʻo i ai faʻamaʻi e leʻi suia ma o le mea lea e le tali atu ai i le faʻatautaia masani o le chemotherapy. O togafitiga mo le CLL/SLL i le lumana'i atonu o le chemotherapy e mafai ona avea ma togafitiga lona lua po'o se laina lona tolu.
A/Prof Constantine Tam ma Deborah Sims - CLL & Mantle Cell Lymphoma.
A/Prof Constantine Tam, Peter MacCallum Cancer Centre, RMH & St Vincent's Hospital na talanoa ia Deborah Sims, mai Lymphoma Ausetalia. Ua tuuina mai e Dr Tam ona malamalamaaga mai mea taua mai le fonotaga i le CLL ma le Mantle cell lymphoma. Na ia tu'uina atu se fa'amatalaga o ana fa'aaliga e 3 sili ona vi'ia mo Chronic Lymphocytic Leukemia (CLL) & Small Lymphocytic Lymphoma (SLL).
Dr George Mulimuli - CLL fa'afouga.
Dr George Follows mai Peretania na talanoa ma Lymphoma Ausetalia i le American Society of Hematology (ASH) fonotaga na faia talu ai nei i Orlando, ISA. O Dr Follows o le Lymphoma/CLL Clinical Lead mo Cambridge ma o loo ia umia foi le tele o tofiga e aofia ai le nofoa o le UK CLL forum. Na ia fa'atalanoaina fa'afouga i su'esu'ega ma fa'ai'uga o su'esu'ega na tu'uina atu ile fonotaga a le ASH ile CLL.
Dr Nitin Jain ma Deborah Sims - Ibrutinib & Venetoclax i gasegase ma CLL.
Dr Nitan Jain o se Polofesa Lagolago i le Matagaluega o Leukemia i le Iunivesite o Texas MD Anderson Cancer Center i Houston, Texas, ISA. Na talanoaina e Dr Nitan ana faʻamatalaga 2 i le taimi o le fonotaga a le ASH o suʻesuʻega e 2 na faia i le MD Anderson Cancer Center e faʻaaoga ai le Ibrutinib ma le venetoclax faʻatasi ma tagata mamaʻi e maua i le lymphocytic leukemia (CLL) tumau i togafitiga muamua ma i latou o loʻo i ai le maʻi toe faʻafoʻi / refractory. I'uga na fa'aalia ai i vaega uma e lua o le tu'ufa'atasiga o togafitiga e fa'aaoga ai le ibrutinib ma le venetoclax ose togafiti fa'agutu e leai se chemotherapy mo tagata mama'i e maua i le CLL ma o le a fa'aauau pea su'esu'ega.
Dr Tanya Siddiqi - CAR T-cell i le CLL toe fa'afo'i/refractory.
Dr Tanya Siddiqi o le Faʻatonu, Chronic Lymphocytic Leukemia Program, Toni Stephenson Lymphoma Center ma A / Prof Department of Hematology & Hematopoietic Transplantation i le City of Hope National Medical Center, Duarte, ISA. Na talanoaina e Dr Siddiqi lana folasaga i le taimi o le fonotaga o le vaega ou te suʻesuʻeina le togafitia o tagata mamaʻi ma le CLL. O gasegase uma na maua muamua a itiiti ifo i le 3 togafitiga masani, e aofia ai le ibrutinib ma le afa o tagata gasegase na maua foi venetoclax. O le suʻesuʻega na togafitia ai le 23 tagata mamaʻi ma le CAR T-cell therapy lea e sili atu i le 80% na maua tali tumau i luga ole 6 masina. E faaauau pea le tulitatao.
Polofesa John Seymour - Va'aiga lautele o le su'esu'ega a Murano - CLL/SLL.
Na tuuina atu e Prof Seymour le suʻesuʻega e fa tausaga o le suʻesuʻega a Murano e faʻamaonia ai le manuia o le taimi faʻatapulaʻa Venetoclax & rituximab i le leukemia lymphocytic (CLL). O le Venetoclax (Ven) o se fa'atosina tautala sili ona filifilia o le fa'atonu o le apoptosis BCL-2, lea e fa'ailoaina i le CLL. MURANO (se su'esu'ega Fa'asologa III Fa'asologa) fa'atusatusa VenR umi fa'atasi ma bendamustine-rituximab (BR) i R/R CLL. O le maualuga o le alualu i luma-saoloto le ola (PFS) o VenR versus BR na faʻatuina i le suʻesuʻega muamua na fuafuaina (Seymour et al. N Engl J Med 2018); fa'aauau le manuia o le PFS na va'aia i le umi o le tulitatao ma ina ua mae'a uma togafitiga.
Polofesa Peter Hillmen - Lu'itau i le CLL/SLL fa'afanua togafitiga.
O lo'o fa'atalanoaina e Polofesa Hillman nisi o lu'itau o le suiga vave o le laufanua o togafitiga mo CLL/SLL fa'atasi ai ma le tele o togafitiga fou i luga o le maketi.
Polofesa Peter Hillmen - CLL faʻafouga mai le ASH 2019.
Na talanoaina e Prof Hillmen nisi o mea taua sili ona taua mai le fonotaga i luga o faʻataʻitaʻiga faʻataʻitaʻiga fou na faʻaaogaina i le laina pito i luma na faʻaalia na faʻaalia ai taunuuga lelei i le faʻaaogaina o le ibrutinib (BTK inhibitor), acalabrutinib (generation BTK inhibitor), venetoclax (BCL2 inhibitor). ) ma le faʻaaogaina o togafitiga faʻatasi. Na ia faʻatalanoaina foʻi faʻataʻitaʻiga faʻataʻitaʻiga i le tulaga toe faʻaalia e faʻaalia ai iʻuga lelei na aofia ai le CAR T-cell therapy. Fa'afetai ile Leukemia Care mo le fa'asoaina o le fa'atalatalanoaga ma le Lymphoma Ausetalia.
Polofesa Miles Prince – su'ega fa'a-gane (CLL/SLL) & togafiti T-cell CAR.
Na talanoaina e Prof Prince ona manatu e uiga i autu autu e fiafia i ai le lymphoma mai le fonotaga. Na ia talanoaina o le auala sili e togafitia ai le lymphoma o se tagata maʻi, o latou suʻesuʻega e tatau ona malamalama ma iloa atoatoa. Ua fa'ailoa mai e mana'omia e tagata mama'i ua maua i le CLL/SLL le su'ega fa'a kenera a'o le'i faia togafitiga. O ma'i e le'i suia ma se TP53 suia CLL/SLL, o le chemotherapy ua fa'aalia e le aoga mo lenei vaega ma'i. I Amerika ma Peretania (ma nisi o atunuu Europa) o loʻo faʻatupeina tagata gasegase e maua ai le Ibrutinib i luma-laina, peitaʻi e le o le tulaga lea i Ausetalia, lea e maua ai e tagata mamaʻi le chemo-immunotherapy ma le ibrutinib i togafitiga lona lua.
Lymphoma sela B Tele (DLBCL)
A/Prof Chan Cheah – Lymphoma Aggressive, Fa'asalalauina Large B Cell lymphomas.
A/Prof Cheah toe iloilo le pepa “Aggressive Lymphoma (Diffuse Large B-cell and other aggressive b-cell non-Hodgkin lymphomas) – iʻuga mai faʻataʻitaʻiga faʻataʻitaʻiga faʻataʻitaʻi: faʻamalieina le chemotherapy pito i luma” sauniga na faia i le Aso Sa 8 Tesema i le ASH 2019.
Dr Jason Westin – Fa'asalalauina fa'afouga Lymphoma tele B-cell & le Su'esu'ega Amata Fa'atamai.
Na talanoaina e Dr Westin nisi o mea taua mai le konafesi i le DLBCL e aofia ai le CAR T-cell therapy ma faʻafouga mai suʻesuʻega e faʻaitiitia ai le chemotherapy ma faʻaleleia ai aʻafiaga oona mo maʻi.
Follicular Lymphoma
Dr Loretta Nastoupil - Follicular lymphoma suʻesuʻega - Vaega 1.
Dr Nastoupil o loʻo faʻatalanoaina taunuuga o lana suʻesuʻega II o le Obintuzumab (ituaiga II anti-CD20 monoclonal antibody) ma Lenalidamide (immunomodulatory agent) i le FL e leʻi togafitia muamua, maualuga le mamafa o le tuma. O lenei tu'ufa'atasiga o togafitiga na va'aia e fa'amalieina lelei ma aoga i se su'esu'ega talu ai mo ma'i na togafitia i le toe fa'afo'i po'o le refractory FL.
Dr Loretta Nastoupil - Follicular lymphoma suʻesuʻega - Vaega 2.
Na talanoaina e Dr Nastoupil taunuuga o lana vaega II suʻesuʻega o le Obintuzumab (ituaiga II anti-CD20 monoclonal antibody) ma Lenalidamide (immunomodulatory agent) i le FL e leʻi togafitia muamua, maualuga le mamafa o le tuma. O su'esu'ega atili o lenei auala aoga, fa'afoma'i puipuia i FL e le'i togafitia e fa'amaonia. Na talanoaina e Dr Nastoupil mafua'aga o lenei faiga lelei ma fa'apalepale mo so'o se faitau aofa'i o tagata mama'i e maua i le follicular lymphoma.
A/Prof Chan Cheah – Follicular lymphoma fa'afouga fa'ata'ita'iga.
Na talanoaina e Dr Cheah se folasaga na saunia e Dr Loretta Nastoupil mai le MD Anderson Cancer Centre, Texas i le fonotaga a le ASH 2019. O le vaega II suʻesuʻega na vaʻavaʻai i le togafitia o tagata mamaʻi Follicular lymphoma e leʻi togafitia muamua ma Obintuzumab (ituaiga II anti-CD20 monoclonal antibody) ma Lenalidamide (immunomodulatory agent), faʻatasi ai ma le mamafa maualuga o le tuma. O lenei tu'ufa'atasiga o togafitiga na va'aia e fa'amalieina lelei ma aoga i se su'esu'ega talu ai mo gasegase na togafitia i le toe fa'afo'i po'o le refractory FL na faia i le MD Anderson Cancer Center e Prof Nathan Fowler (su'esu'ega RELEVANCE).
Dr Allison Barraclough -Nivolumab + Rituximab ile First-line Follicular Lymphoma.
Na talanoaina e Dr Barraclough i'uga le tumau o se su'esu'ega muamua i le vaega II o le lalolagi, o lo'o ta'ita'ia e Dr Eliza Hawkes, le pulega pito i luma o tagata mama'i e maua i le tulaga 1-3A follicular lymphoma. O le suʻesuʻega e faʻaaogaina ai le tuʻufaʻatasia o le puipuiga o le puipuiga, naʻo le faʻataʻitaʻiga muamua i le tulaga toe faʻafoʻi. E maua e tagata ma'i le nivolumab mo na'o le 8 vaiaso muamua ma afai latou te ausia se tali atoatoa, o le a fa'aauau pea ma le sui tasi nivolumab. Mo i latou e naʻo le mauaina o se tali faʻapitoa o le a alu i luga o le tuʻufaʻatasia o le nivolumab ma le rituximab. Sa lelei fa'ai'uga i luga ole aofa'iga ole tali (ORR) o le 80% ma e sili atu i le afa o nei gasegase na maua se tali atoatoa (CR). Sa i ai se tulaga maualalo oona, lea na mafai ai e le tele o gasegase ona galulue pea ma faaauau ai gaioiga masani o le olaga
Mantle Cell Lymphoma
Dr Sasanka Handunetti - Mantle Cell Lymphoma (Fa'afouina ole su'esu'ega AIM).
Na talanoaina e Dr Handunetti lana faʻamatalaga e uiga i le tolu-tausaga faʻafouina o le vaega II AIM suʻesuʻega (TAM, et al, NEJM 2018) faʻatautaia i le Peter MacCallum Cancer Center i Melepone, e faʻaaoga ai le BTK inhibitor ibrutinib ma le BCL-2 inhibitor venetoclax togafitiga i gasegase ma fa'aletonu le fa'ai'uga o le lymphoma sela (MCL). Fa'ai'uga na fa'aalia ai le fa'agasologa o le alualu i luma o le ola fua o le 29 masina. Na tulaʻi mai ai le fesili e iai se avanoa e faʻatapulaʻaina le umi o togafitiga faʻatatau-agent i le puleaina o le MCL toe faʻafoʻi pe faʻafefe.
Polofesa Steven Le Gouill - Mantle Cell Lymphoma suʻesuʻega.
Na talanoaina e Prof Le Gouill lana vaega ou te suʻesuʻeina mo le MCL fou faatoa maua e faʻaaoga ai Ibrutinib, Venetoclax ma Obintuzumab ua uma ona faʻaalia muamua e iai le aoga i le toe faʻafoʻi / refractory tulaga o ni sui e tasi ma faʻatasi i le relapsed / refractory (R / R) MCL. . Na ia tuʻuina atu foʻi se faʻamatalaga lautele o le tulaga o le tausiga mo tagata mamaʻi ma le MCL mo le maʻi laʻititi ma le maʻi matua i le laina pito i luma ma le R / R pulega.
Polofesa Simon Tulafono – Mantle Cell Lymphoma Update.
Na talanoaina e Prof Simon Rule lana faʻasalalauga faʻasalalau i le fonotaga e vaʻavaʻai i le 7.5 tausaga le tulitatao o tagata mamaʻi ua toe faʻafoʻi pe faʻafefe MCL o loʻo faʻamaʻi i le ibrutinib (BTK inhibitor) na faʻaalia ai se numera tele o tagata mamaʻi o loʻo i ai pea i le faʻamagaloga sili atu nai lo le 5 tausaga. Na faʻaalia ai foi o tagata mamaʻi na mauaina le Ibrutinib i laina muamua o togafitiga na sili atu le umi o le tali atu, nai lo i latou na mauaina tuai.
KTE-X19: Ose T-Cell Filifiliga mo le Mantle Cell Lymphoma?
E ivasefulutolu pasene o tagata mama'i ua toe fo'i/refractory matle cell lymphoma (MCL) na tali atu i togafitiga ma le KTE-X19, o se autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, e tusa ai ma taunuuga mai le suesuega a le ZUMA-2 na tuuina atu. i le Fonotaga Faaletausaga ASH 2019.
Hodgkin Lymphoma
Dr Jessica Hochberg – Chemotherapy, Talavou Matutua & Hodgkin Lymphoma.
Ole fua ole fa'amālōlōina mo Hodgkin Lymphoma fou ua maua e maualuga ile fa'aogaina tu'ufa'atasi ole chemoradiotherapy. Ae ui i lea, o lenei mea e masani ona iʻu ai i le faʻaleagaina o le tino ma le mafaufau faʻapitoa e mafai ona matua aʻafia ai le lelei o le olaga i tagata o totoe. O le faʻaopoopoga o le Brentuximab vedotin ma le Rituximab i le tuʻufaʻatasia o le lamatiaga o le chemotherapy (e aunoa ma le cyclophosphamide, etoposide poʻo le bleomycin) mo le Hodgkin Lymphoma fou faatoa maua e foliga mai e saogalemu i tamaiti, talavou ma talavou matutua. O a matou faʻaiʻuga o loʻo faʻaalia ai le folafolaga taua ma le fua faatatau o le CR o le 100%, 58% vave vave tali ma le faʻaitiitia tele o le faʻaogaina o le chemotherapy ma le radiation. O le EFS / OS i le taimi nei o le 100% faʻatasi ai ma le vaeluaga o le tulitatao taimi e sili atu nai lo 3.5 tausaga.
Polofesa Andrew Evens - HoLISTIC Hodgkin Lymphoma Suʻesuʻega Faʻavaomalo.
Polofesa Evens o se sui malosi o le HoLISTIC (Hodgkin Lymphoma International Study for Individual Care) - o se faʻapotopotoga faʻavaomalo o loʻo tuʻufaʻatasia se 'au o tagata atamamai eseese mai le salafa o le lalolagi e suʻesuʻe vaega iloga o le faʻamaʻi o le lymphoma Hodgkin, faʻamaʻi pipisi, togafitiga, ola ma taunuuga o le soifua maloloina. i vaitausaga uma. O lo'o fa'amaopoopoina fa'amaumauga o gasegase ta'ito'atasi mai le silia ma le 20 fa'ata'ita'iga fa'aonaponei mai Amerika i Matu ma Europa o vaitausaga uma fa'apea fo'i ma le 6 fa'alapotopotoga ma fa'aitulagi lymphoma resitara o Hodgkin, ma le tele o fa'ata'ita'iga oncology. O la latou sini o le faʻaleleia lea o le faia o faʻaiuga mo tamaiti ma tagata matutua Hodgkin lymphoma maʻi ma tagata e tuʻuina atu, tuʻuina atu le faʻalauteleina o togafitiga ma i le leai o se faʻamatalaga faʻamaʻi faʻamaʻi ma umi umi.
Dr Stephen Ansell ma Deborah Sims - Hodgkin Lymphoma.
O Dr Ansell ose ta'ita'i fa'apitoa ile non-Hodgkin lymphoma ma Hodgkin lymphoma ile Mayo Clinic, ISA. Na saunoa Dr Ansell e uiga i le Hodgkin lymphoma - o le togafitiga o laina pito i luma i le ASH lea faatoa ia auai. O le sauniga na faʻaalia ai se faʻataʻitaʻiga faʻataʻitaʻiga lea na faʻaogaina atili ai i togafitiga fou i le laina pito i luma, lea e faʻaopoopoina ai le Brentuximab Vedotin & a PD-1 inhibitor ma faʻaitiitia ai nisi o le chemotherapy masani na bleomycin, na faʻaalia ai taunuuga mataʻina. O taunuʻuga na faʻaititia ai foi le oona mo tagata mamaʻi o loʻo mauaina lenei togafitiga pe a faʻatusatusa i togafitiga masani. O togafitiga masani i le lymphoma Hodgkin e maualuga i luga o tali uma e tusa ma le 90% o tagata maʻi e oʻo i se tali atoatoa. O le tele o faʻataʻitaʻiga i Hodgkin lymphoma o loʻo faʻamoemoe i le taimi nei e faʻaitiitia ai faʻamatalaga oona ma aʻafiaga tuai mo nei gasegase.
Lymphoma sone pito i tua
Dr Sasanka Handunetti - Su'esu'ega Vaega II ile Lymphoma Fa'ata'ita'i Po'o Fa'asa'o.
Na talanoaina e Dr Handunetti se faʻasalalauga faʻasalalau mai le 'au i le Peter MacCallum Cancer Center i le taimi o le fonotaga o le faʻaaogaina o le ibrutinib faʻatasi ma le venetoclax mo tagata mamaʻi ua toe faʻafoʻi pe refractory Marginal Zone Lymphoma (MZL). O le MZL ose ma'i e le mafai ona fa'amālōlōina e leai se fa'ata'ita'iga o togafitiga ile tulaga toe fa'afo'i po'o le fa'ama'i. O nei vailaʻau uma e lua na vaʻaia e iai faʻamaoniga o le gaioiga ma le faʻamalieina e pei o monotherapies (tagata nofofua) ma o lenei suʻesuʻega na faʻamoemoe e iloilo le tali o se togafitiga tuʻufaʻatasia.
Lymphoma fa'aletino tutotonu
Dr Katherine Lewis - Primary Central Nervous System Lymphoma (PCNSL).
Na talanoaina e Dr Lewis se faʻasalalauga faʻasalalau i le ASH 2019 na vaʻavaʻai i taunuʻuga mo tagata mamaʻi ma le fatugalemu o le tino (faiʻai ma le tui) lymphoma na togafitia i le Ibrutinib (BTK inhibitor). Ole lymphoma e seasea ma fa'alavelave lea e le lelei le fa'ama'i o lenei vaega ma'i ma e masani ona togafitia i le tu'ufa'atasiga o le chemotherapy regimens. O se su'esu'ega tuai lea na aoina mai ai fa'amatalaga mai Ausetalia atoa ma Niu Sila o 16 gasegase na togafitia i le monotherapy Ibrutinib i le tulaga toe fa'afo'i/fa'asa. E ui lava o se numera toʻaitiiti o tagata mamaʻi, o taunuʻuga na faʻamoemoeina, faʻatasi ai ma tali e oʻo atu i le 81%.
Waldenstrom's Macroglobulinemia
Polofesa Mathias Rummel – Waldenstrom's Macroglobulinemia & le faamasinoga a StiL.
Ufiufi le 2-tausaga i'uga pe a mae'a su'esu'ega StiL va'ai ile tausiga Rituximab vs mata'ituina post bendamustine-rituximab. I'uga e fa'aalia ai o le tausiga o le rituximab e le fa'aleleia ai le ola atoa. O lo'o tu'uina mai fo'i e Prof Rummel se aotelega o le pulega o lo'o iai nei a le WM.
T-cell Lymphoma
Lymphoma sela T pito pito
Dr Jasmine Zain, MD - talanoaina suʻesuʻega sili ona mataʻina i le PTCL na tuʻuina atu ile ASH 2019.
(Fa'afetai ile OBRoncology).
Dr. Zain, Faʻatonu o le T-cell Lymphoma Program, Matagaluega o Hematology ma Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, faʻatalanoaina suʻesuʻega sili ona manaia i le togafitiga o le lymphoma T-cell peripheral (PTCL) o loʻo tuʻuina atu i le ASH 2019.
Dr Jasmine Zain - Faʻafefea ona faʻaleleia togafitiga mo le lymphoma T-cell peripheral.
(Fa'afetai ile OBRoncology).
Dr. Zain, Fa'atonu o le T-cell Lymphoma Program, Matagaluega o Hematology ma Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, Aai o le Faamoemoe, mafaufau pe fa'afefea ona fa'atupuina togafitiga T-cell lymphoma (PCL) i tausaga talu ai nei.
Dr Jasmine Zain - Tala fou auala e togafitia ai le PTCL e aofia ai le CAR T-cell therapy.
(Fa'afetai ile OBRoncology).
Dr. Zain, Faatonu o le T-cell Lymphoma Program, Matagaluega o Hematology ma Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, Aai o le Faamoemoe, o loʻo taʻu mai ia i tatou nisi o auala fou i le atinaʻeina mo le togafitiga o le lymphoma T-cell peripheral ( PTCL).
Dr Timothy Illidge, faʻamatalaina le faʻamoemoega o le faʻamoemoeina o le PTCL.
(Fa'afetai ile OBRoncology).
Dr. Illidge, Polofesa o Togafitiga ma Oncology, Vaega o Saienisi o Kanesa, O le Falemai Christie, Iunivesite o Manchester, o loʻo faʻamatalaina le faʻamoemoega o le tulimataʻiina o le lymphoma t-cell peripheral (PTCL).
